PT - JOURNAL ARTICLE AU - Tsukasa Masuda AU - Nobuyuki Tanaka AU - Kimiharu Takamatsu AU - Kyohei Hakozaki AU - Ryohei Takahashi AU - Tadatsugu Anno AU - Ryohei Kufukihara AU - Kazunori Shojo AU - Shuji Mikami AU - Toshiaki Shinojima AU - Kazuhiro Kakimi AU - Tatsuhiko Tsunoda AU - Eriko Aimono AU - Hiroshi Nishihara AU - Ryuichi Mizuno AU - Mototsugu Oya TI - Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer AID - 10.1136/jitc-2021-003883 DP - 2022 Mar 01 TA - Journal for ImmunoTherapy of Cancer PG - e003883 VI - 10 IP - 3 4099 - http://jitc.bmj.com/content/10/3/e003883.short 4100 - http://jitc.bmj.com/content/10/3/e003883.full SO - J Immunother Cancer2022 Mar 01; 10 AB - Background The aims of this study were (1) to clarify the impact of tertiary lymphoid structure (TLS) status on the outcome and immunogenomic profile of human clear cell renal cell carcinoma (ccRCC) and (2) to determine phenotypic differences in TLSs between different types of genitourinary cancer, that is, urinary ccRCC and bladder cancer.Methods We performed a quantitative immunohistological analysis of ccRCC tissue microarrays and conducted integrated genome mutation analysis by next-generation sequencing and methylation array analysis. Since the tumor immune microenvironment of ccRCC often differs from that of other cancer types, we analyzed the phenotypic differences in TLSs between ccRCC and in-house bladder cancer specimens.Results Varying distribution patterns of TLSs were observed throughout ccRCC tumors, revealing that the presence of TLSs was related to poor prognosis. An analysis of genomic alterations based on TLS status in ccRCC revealed that alterations in the PI3K-mTOR pathway were highly prevalent in TLS-positive tumors. DNA methylation profiling also revealed distinct differences in methylation signatures among ccRCC samples with different TLS statuses. However, the TLS characteristics of ccRCC and bladder cancer markedly differed: TLSs had the exact opposite prognostic impact on bladder cancer as on ccRCC. The maturity and spatial distribution of TLSs were significantly different between the two cancer types; TLSs were more mature with follicle-like germinal center organization and likely to be observed inside the tumor in bladder cancer. Labeling for CD8, FOXP3, PD-1, and PD-L1 showed marked differences in the diversity of the immune microenvironment surrounding TLSs. The proportions of CD8-, FOXP3-, and PD-L1-positive cells were significantly higher in TLSs in bladder cancer than in TLSs in ccRCC; rather the proportion of PD-1-positive cells was significantly higher in TLSs in ccRCC than in TLSs in bladder cancer.Conclusion The immunobiology of ccRCC is unique, and various cancerous phenomena conflict with that seen in other cancer types; therefore, comparing the TLS characteristics between ccRCC and bladder cancer may help reveal differences in the prognostic impact, maturity and spatial distribution of TLSs and in the immune environment surrounding TLSs between the two cancers.Data are available on reasonable request. The data will be shared on reasonable request to the corresponding author.